Literature DB >> 23107489

Catheter-based endomyocardial delivery of mesenchymal precursor cells using 3D echo guidance improves cardiac function in a chronic myocardial injury ovine model.

Yanping Cheng1, Genghua Yi, Gerard B Conditt, Alexander Sheehy, Frank D Kolodgie, Armando Tellez, Igor Polyakov, Anguo Gu, Michael S Aboodi, David Wallace-Bradley, Michael Schuster, Timothy Martens, Silviu Itescu, Greg L Kaluza, Shubhayu Basu, Renu Virmani, Juan F Granada, Warren Sherman.   

Abstract

The administration of bone marrow-derived stem cells may provide a new treatment option for patients with heart failure. Transcatheter cell injection may require multi-imaging modalities to optimize delivery. This study sought to evaluate whether endomyocardial injection of mesenchymal precursor cells (MPCs) could be guided by real-time 3D echocardiography (RT3DE) in treating chronic, postinfarction (MI) left ventricular (LV) dysfunction in sheep. Four weeks after induction of an anterior wall myocardial infarction in 39 sheep, allogeneic MPCs in doses of either 25 × 10(6) (n = 10), 75 × 10(6) (n = 9), or 225 × 10(6) (n = 10) cells or nonconditioned control media (n = 10) were administered intramyocardially into infarct and border zone areas using a catheter designed for combined fluoroscopic and RT3DE-guided injections. LV function was assessed before and after injection. Infarct dimension and vascular density were evaluated histologically. RT3DE-guided injection procedures were safe. Compared to controls, the highest dose MPC treatment led to increments in ejection fraction (3 ventricula 3% in 225M MPCs vs. -5 ± 4% in the control group, p < 0.01) and wall thickening in both infarct (4 ± 4% in 225M MPCs vs. -3 ± 6% in the control group, p = 0.02) and border zones (4 ± 6% in 225M MPCs vs. -8 ± 9% in the control group, p = 0.01). Histology analysis demonstrated significantly higher arteriole density in the infarct and border zones in the highest dose MPC-treated animals compared to the lower dose or control groups. Endomyocardial implantation of MPCs under RT3DE guidance was safe and without observed logistical obstacles. Significant increases in LV performance (ejection fraction and wall thickening) and neovascularization resulted from this technique, and so this technique has important implications for treating patients with postischemic LV dysfunction.

Entities:  

Mesh:

Year:  2012        PMID: 23107489     DOI: 10.3727/096368912X658016

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

Review 1.  Preclinical Studies of Stem Cell Therapy for Heart Disease.

Authors:  Bryon A Tompkins; Wayne Balkan; Johannes Winkler; Mariann Gyöngyösi; Georg Goliasch; Francisco Fernández-Avilés; Joshua M Hare
Journal:  Circ Res       Date:  2018-03-30       Impact factor: 17.367

2.  Safety and feasibility of mapping and stem cell delivery in the presence of an implanted left ventricular assist device: a preclinical investigation in sheep.

Authors:  Yi Zheng; Luiz C Sampaio; Ke Li; Guilherme V Silva; Maria Cabreira-Hansen; Deborah Vela; Ana Maria Segura; Christina Bovè; Emerson C Perin
Journal:  Tex Heart Inst J       Date:  2013

3.  Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.

Authors:  Kenneth M Borow; Alex Yaroshinsky; Barry Greenberg; Emerson C Perin
Journal:  Circ Res       Date:  2019-07-18       Impact factor: 17.367

Review 4.  Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier.

Authors:  Merlin Sobia Poomani; Iyyadurai Mariappan; Ramachandran Perumal; Rathika Regurajan; Krishnaveni Muthan; Venkatesh Subramanian
Journal:  Glob Heart       Date:  2022-03-03

Review 5.  Efficacy of Stem Cell Therapy in Large Animal Models of Ischemic Cardiomyopathies: A Systematic Review and Meta-Analysis.

Authors:  Debora La Mantia; Chiara Bernardini; Augusta Zannoni; Roberta Salaroli; Changzhen Wang; Silvia Bencivenni; Monica Forni
Journal:  Animals (Basel)       Date:  2022-03-16       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.